I. Samaratunga

VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.

G. Mufti, A. Mijovic, J. Singer, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia

B. Czepulkowski, A. Mijovic, R. Grace, 1997, British journal of haematology.

171 Idarubicin, fludarabine, cytarabine and G-CSF (FLAG-IDA) for the treatment of high risk MDS or AML

G. Mufti, A. Mijovic, R. Grace, 1997 .

Myelodysplasia syndromes during pregnancy

G. Mufti, P. Fenaux, A. Pagliuca, 1991, European journal of haematology.

"Pre-B" phenotypes in blast crisis of Ph1 positive CML: evidence for a pluripotential stem cell "target".

M. Greaves, M. Greaves, A. Hoffbrand, 1979, Leukemia research.

Screening for glucose‐6‐phosphate dehydrogenase deficiency prior to dapsone therapy

A. Pembroke, I. Samaratunga, P. Todd, 1994, Clinical and experimental dermatology.